US 12,268,659 B2
Methods and compositions for treating cannabis use disorder and mitigating cannabinoid withdrawal
Ginger D. Constantine, Malvern, PA (US)
Assigned to Pleopharma, Inc., Phoenixville, PA (US)
Filed by PleoPharma, Inc., Phoenixville, PA (US)
Filed on Aug. 30, 2021, as Appl. No. 17/461,540.
Application 17/461,540 is a continuation in part of application No. 17/244,585, filed on Apr. 29, 2021, granted, now 11,197,846.
Application 17/244,585 is a continuation in part of application No. PCT/US2021/020921, filed on Mar. 4, 2021.
Claims priority of provisional application 62/985,097, filed on Mar. 4, 2020.
Prior Publication US 2022/0079904 A1, Mar. 17, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/352 (2006.01); A61K 31/195 (2006.01); A61K 31/196 (2006.01); A61P 25/30 (2006.01)
CPC A61K 31/196 (2013.01) [A61K 31/352 (2013.01); A61P 25/30 (2018.01)] 24 Claims
 
1. A method of treating cannabis withdrawal syndrome, comprising administering to a patient in need thereof therapeutically effective daily doses of nabilone and gabapentin, wherein the nabilone daily dose is from 5 to 7 mg per day and the gabapentin daily dose is from 50 to 700 mg per day and wherein the daily doses are administered for a period of time of between two to seven days, where said treatment improves sleep quality, sleep duration or quantity, sleep depth or reduces sleep difficulty.